Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

NewLimit, an anti-aging biotech startup backed by Coinbase CEO Brian Armstrong, raised a $130 million Series B round.

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on ...

Eli Lilly said the revision reflects a $1.57 billion deal charge recorded in the first quarter, which is primarily related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics.

Eli Lilly (NYSE: NYSE:LLY) is set to report its first-quarter earnings on Thursday, May 1st, before the market opens. Analysts expect the drugmaker to earn $3.46 (+34.1% Y/Y) on revenue of $12.72B ...

Compared to the aggregate P/E ratio of 24.32 in the Pharmaceuticals industry, Eli Lilly Inc. has a higher P/E ratio of 75.59. Shareholders might be inclined to think that Eli Lilly Inc. might ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (NYSE: LLY). It is the most valuable healthcare company in the world, with a market ...